Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2026Clinical Colorectal CancerOpen Access

Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMatthew BurgeRoyal Brisbane and Women's HospitalJTJeanne TiePeter MacCallum Cancer CentreTKTharani KrishnanFlinders Medical Centre

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Burge et al. (2026) studied this question.

synapsesocial.com/papers/6a0f253c4994b59e7742637chttps://doi.org/10.1016/j.clcc.2026.04.001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).2024 · 6 citations
  2. 2Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer2023 · 468 citations
  3. 3Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-082020 · 48 citations
  4. 4Liver transplantation in metastatic colorectal cancer: are we ready for it?2023 · 43 citations